SANTA MONICA, Calif. - GoodRx Holdings, Inc. (NASDAQ:GDRX), a company known for providing prescription savings in the United States, has made a significant announcement regarding changes in its leadership structure. Interim CEO Scott Wagner has agreed to extend his commitment to the company, a decision that comes amidst the resignation of two board members.
Stephen LeSieur will depart from the board effective today, with Adam Karol following suit on March 22, 2024. Both have been instrumental in the company's evolution, with LeSieur joining the board in 2015 and Karol in 2018. Their departures are seen as a natural transition, given their long tenures and recent corporate developments, including the repurchase of a portion of Spectrum's shares.
Trevor Bezdek, co-founder and Chairman of the Board, expressed gratitude for the contributions of Mr. LeSieur and Mr. Karol, acknowledging the pivotal roles they played at GoodRx. He also mentioned the company's ongoing collaboration with the Silver Lake team, highlighting Greg Mondre, Co-Chief Executive Officer of Silver Lake, who will continue serving on the board.
GoodRx, since its inception in 2011, has been committed to offering consumers transparent and lower prices for medications. The company's services have led to nearly $70 billion in consumer savings and have made the GoodRx app one of the most downloaded medical apps over the past decade.
The company regularly updates investors through its investor relations website and complies with disclosure obligations under Regulation FD. This commitment to transparency includes issuing press releases, filing reports with the Securities and Exchange Commission, and hosting public conference calls and webcasts.
This announcement is based on a press release statement and contains forward-looking statements regarding the company's leadership and board composition. GoodRx's actual results could differ due to various risks and uncertainties, which are detailed in their filings with the SEC.
The recent leadership changes at GoodRx reflect the company's ongoing efforts to strengthen its market position and continue delivering growth, as affirmed by Interim CEO Scott Wagner.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.